Stacking
Interaction Unknown
BPC-157 and TB-500 are the most commonly co-administered peptides in recovery protocols and no adverse interactions have been reported in either animal studies or user reports. Their mechanisms are complementary — BPC-157 addresses inflammatory signalling, TB-500 promotes cell migration — but no co-administration RCT exists.